石藥集團(01093.HK):抗腫瘤藥“SYHA1815片”獲臨牀試驗批件
格隆匯 8 月 24日丨石藥集團(01093.HK)發佈公告,公司附屬公司上海潤石醫藥科技有限公司開發的“SYHA1815片”已獲國家藥品監督管理局批准在中國開展臨牀試驗。
根據披露,該產品為中國科學院上海藥物研究所與上海潤石共同開發的多靶點抑制劑。本次獲批的臨牀適應症為不可切除的局部晚期或轉移性實體瘤(包括甲狀腺癌、非小細胞肺癌、胃癌(胃食管結合部癌)、結直腸癌、胰腺癌、軟組織肉瘤等)。臨牀前研究表明,該產品通過高活性抑制多種激酶,對包括甲狀腺癌、非小細胞肺癌、胃癌等多種腫瘤具有良好的效果,同時具有良好的安全性和藥代動力學特點,極有希望在臨牀試驗中展現出良好的抗腫瘤效果。集團將全力以赴推進該產品的臨牀研究工作,力爭該產品儘快上市。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.